|Videos|November 10, 2016

Why is Legionnaires' on the Rise in the US?

Laura Cooley, MD, MPH, medical epidemiologist, Respiratory Diseases Branch, Division of Bacterial Disease, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, explains the current Legionella situation.

Laura Cooley, MD, MPH, medical epidemiologist, Respiratory Diseases Branch, Division of Bacterial Disease, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, explains the current Legionella situation.

Interview Transcript (slightly modified for readability)

“[So far], 2016 [has been] a big year for Legionella and Legionnaires’ disease. It was 40 years ago that the first outbreak was investigated, and in the intervening years tremendous amount of progress has been made, particularly [with] understanding risk factors for legionnaires disease and the relationship of Legionella with the environment and building water-systems. But even with all this progress, the reported number of cases continues to rise; and, in fact, in 2014, there was a 286% increase when compared with the year 2000 as far as [the] reported cases of Legionnaires’ disease. There’s a lot of work yet to be done.

In 2014 there were about 5000 cases reported. We think that this is probably an underestimate. The reason for this increase for reported cases is not exactly clear, [it’s] probably multi-factorial. Some of it could have to do with better surveillance, better awareness of testing, [or] better testing mechanisms. But there is reason to believe that there is also an increase in [the] disease itself, [which] that could be due to a number of factors as well, [such as] an increase in the number of people at risk for Legionnaires’ disease, so an aging US population; more people on immunocompromising medications; also it could have to do with aging infrastructure in the United States, so older plumbing systems; and then the climate could be playing a role with warmer temperatures.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.